AC Immune (ACIU) Jefferies London Healthcare Conference 2024 summary

Investment highlights and pipeline overview

• Pipeline is balanced between short- and long-term assets, with both partnered and non-partnered programs.

• Leadership in precision medicine and active immunotherapy, leveraging SupraAntigen and Morphomer platforms.

• Partnerships have generated $450 million, with potential for over $4 billion in future milestones and royalties.

• Financial runway extends into 2027, supporting key catalysts and accelerated immunotherapy investment.

• Focus on breakthrough innovations, including ADCs with enhanced brain penetration.

Clinical and preclinical program updates

• Three active immunotherapies in phase II, including ACI-24 (partnered with Takeda), ACI-35 (with Janssen), and ACI-7104 (wholly owned, for Parkinson's).

• Preclinical assets target neurodegeneration, including alpha-synuclein, Tau, and NLRP3.

• Diagnostic tracers for alpha-synuclein and TDP-43 are first-in-world, supporting precision medicine.

• Seed amplification assays and biomarkers enable targeted neurodegeneration therapies.

Parkinson's disease portfolio and recent data

• Parkinson's portfolio includes three therapeutics and one diagnostic, with ACI-7104 in phase II.

• ADC approach combines antibodies and small molecules for higher brain penetration and efficacy.

• Recent phase II part one data for ACI-7104 showed strong safety and robust immune response, with no serious adverse events.

• Proof-of-concept study expansion to 150 patients aims for early biomarker identification and pivotal development.